Skip to main content
Journal cover image

Redefining hormone resistance in prostate cancer.

Publication ,  Journal Article
Hoimes, CJ; Kelly, WK
Published in: Ther Adv Med Oncol
March 1, 2010

Prostate cancer relies on signaling through the androgen receptor (AR) for maintenance and progression; and androgen-deprivation therapy remains a cornerstone of treatment for advanced prostate cancer. An effective clinical classification of prostate cancer should account for the extent of the disease as well as the mechanisms that are driving the growth of the tumor. The previous terms hormone-sensitive and hormone-refractory described response to treatment. It has become clear that these terms do not reflect the mechanism of disease relapse; however over the last decade there has been a better understanding of androgen-receptor mediated signaling effects and incomplete suppression of androgens in prostate cancer. The Prostate Cancer Clinical Trials Working Group 2 (PCWG2) now recommends addressing the spectrum of clinical states based on castration status as this ligand-centered terminology can more accurately describe the patients' disease, and ultimately provides a useful framework for patient management and drug development. Optimized use of androgen-deprivation therapy, low molecular weight inhibitors of adrenal androgen biosynthesis, and new AR antagonists are promising new therapeutics that can further define the meaning of castrate state. As hormone resistance is redefined to include patients that are refractory to treatments that ablate adrenal and in situ tumoral androgens, a meaningful new clinical state in patients will be forged. We propose a model for incorporating these patients into the current PCWG2 conceptualization of the disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ther Adv Med Oncol

DOI

ISSN

1758-8340

Publication Date

March 1, 2010

Volume

2

Issue

2

Start / End Page

107 / 123

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hoimes, C. J., & Kelly, W. K. (2010). Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol, 2(2), 107–123. https://doi.org/10.1177/1758834009356433
Hoimes, Christopher J., and W Kevin Kelly. “Redefining hormone resistance in prostate cancer.Ther Adv Med Oncol 2, no. 2 (March 1, 2010): 107–23. https://doi.org/10.1177/1758834009356433.
Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol. 2010 Mar 1;2(2):107–23.
Hoimes, Christopher J., and W. Kevin Kelly. “Redefining hormone resistance in prostate cancer.Ther Adv Med Oncol, vol. 2, no. 2, Mar. 2010, pp. 107–23. Pubmed, doi:10.1177/1758834009356433.
Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol. 2010 Mar 1;2(2):107–123.
Journal cover image

Published In

Ther Adv Med Oncol

DOI

ISSN

1758-8340

Publication Date

March 1, 2010

Volume

2

Issue

2

Start / End Page

107 / 123

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis